Umbilical cord blood donation public or private

Since the first umbilical cord blood transplantation (UCBT) in France in 1988, the growth of UCB banking to support the burgeoning interest in UCBT has been considerable. In 1991, Dr Pablo Rubinstein established the first unrelated UCB bank at the New York Blood Center supported by a pilot grant from the National Heart, Lung and Blood Institute. Since that time, > 160 public UCB banks have been established worldwide and there are ∼730 000 UCB units available for public use.

Umbilical Cord Blood Platelet Lysate as Serum Substitute in Expansion of Human Mesenchymal Stem Cells

The therapeutic potential of human mesenchymal stem cells (hMSCs) has been demonstrated by numerous clinical trials (1). Their differentiation potential into adipocytes, cartilages, and osteocytes support treatment of bone and cartilage diseases, their immune modulating role, increased therapeutic approaches for the treatment of autoimmune diseases, as well as the reduction of graft-versus-host responses (2-4).

Umbilical cord tissue cryopreservation a short review

In 1974, umbilical cord blood (UCB) was reported to be a source of hematopoietic stem and progenitor cells [1], and in 1988, the first transplantation of cryopreserved UCB to an infant with Fanconi anemia, an inherited bone marrow disease, was performed in France [2].

Umbilical cord-derived mesenchymal stromal cells predictive obstetric factors for cell proliferation and chondrogenic differentiation

Due to their capacity for self-renewal, their ability to differentiate into multiple lineages [1], and their immu-noregulatory and anti-inflammatory properties [2, 3], mesenchymal stromal cells (MSC) are promising tools for new cell and tissue engineering developments for re-generative medicine and autoimmune/inflammatory disorders.

Umbilical cord-derived Whartons jelly for regenerative medicine applications

Ligament, muscle, and tendon injuries produce pain, loss of function, instability, and secondary osteoarthritis [1, 2]. Traditionally, these injuries have been managed using activity modification; physical therapy; pharmacological agents, such as non-steroidal anti-inflammatory drugs, corticosteroids, viscosupplementation, and narcotics; and surgical procedures when conservative management fails [3].

Viability and neural differentiation of mesenchymal stem cells

Hypoxia-ischemia in newborns leads to acute morbidity, significant mortality and long-term disability. In neonates who develop moderate to severe acute encephalopathy following delivery room resuscitation, approximately half die and a third of the survivors develop long-term neurological deficits.

Whartons Jelly Derived Mesenchymal Stem Cells Future of Regenerative Medicine Recent Findings and Clinical Significance

Interest in mesenchymal stem cells has been kindled in 1960s as the result of Friedenstein’s observations who reported that the bone marrow stroma can generate bone [1]. It was later shown that bone marrow stromal cells have chondrogenic and adipogenic properties and a high ability for self-renewal [2].

Whartons Jelly Mesenchymal Stem Cells Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy Results from a Retrospective Study

Cerebral palsy (CP) is the most common motor disorder in children [1], decreasing their quality of life (QoL) and level of self-sufficiency (SS). A meta-analysis of 30 out of 1366 papers describing this disability revealed that 3 in 4 CP patients were in pain, 1 in 2 had an intellectual disability, 1 in 3 could not walk, 1 in 3 had hip displacement, and 1 in 4 could not talk. In addition, 1 in 4 CP patients had epilepsy, 1 in 4 had a behaviour disorder, 1 in 4 had bladder control problems, 1 in 5 had a sleep disorder, 1 in 5 dribbled, 1 in 10 was blind, 1 in 15 was tube-fed, and 1 in 25 was deaf [2].

Whartons Jelly Mesenchymal Stem Cells Various Protocols for Isolation and Differentiation of Hepatocyte-Like Cells Narrative Review

Chronic liver failure, such as cirrhosis, can be stimulated by viral hepatitis, metabolic diseases, alcohol, drugs, and autoimmune processes. Liver transplantation is the most popular procedure for chronic liver disease.

Whartons jelly-derived mesenchymal cells as a new source for the generation of microtissues for tissue engineering applications

Tissue engineering (TE) has the aim to develop bio-artificial substitutes to repair or replace damaged tissues and organs (Alaminos et al. 2006; Philips et al. 2018). To generate bio-artificial tissues by TE, three basic elements are needed: cells, biomaterials and growth factors (Carriel et al. 2014).

Whartons Jelly-Derived Mesenchymal Stem Cells Phenotypic Characterization and Optimizing Their Therapeutic Potential for Clinical Applications

The advent of stem cells as a tool to decipher the cell’s biology and as a source of transplant therapy to correct aging and diseases has become a core research arena for tissue engineering and regenerative medicine. A pivotal source of stem cells is the umbilical cord’s Wharton’s jelly (WJ) [1].

Whartons Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease

Allogeneic hematopoietic cell transplantations (allo-HCT) are increasingly used as a treatment for management of hematologic malignancies, bone marrow failure syndromes, and inborn errors of metabolism [1]. They are often complicated by graft-versus-host disease (GVHD), a common cause of non-relapse morbidity and mortality.

Wharton’s Jelly Mesenchymal Stem Cells, Various Protocols…

Chronic liver failure, such as cirrhosis, can be stimulated by viral hepatitis, metabolic diseases, alcohol, drugs, and autoimmune processes. Liver transplantation is the most popular procedure for chronic liver disease.

Scroll to Top